Marimed (MRMD) Q1 2026 earnings summary

Executive summary

• Revenue grew 4% year-over-year in Q1 2026 to $39.5M, driven by expanded wholesale and retail distribution despite industry pricing pressure.

• Retail transactions increased 8% year-over-year, with 55% of Q1 2026 revenue from retail and 44% from wholesale.

• Continued execution of the 'Expand the Brand' strategy increased market reach and brand strength.

• Maintained or grew market-leading positions in key product categories across wholesale markets.

• Positive operating cash flow was generated in a seasonally softer quarter, maintaining 25 consecutive quarters of positive Adjusted EBITDA.

Financial highlights

• Q1 2026 revenue: $39.5 million; GAAP gross margin: 38.7%; Non-GAAP gross margin: 40.1%.

• GAAP net loss: $3.8 million, improved from $5.5 million year-over-year; Non-GAAP net loss: $3.2 million, improved from $3.9 million.

• Adjusted EBITDA: $3.6 million, up from $2.5 million; Adjusted EBITDA margin: 9.1% vs. 7%.

• Positive operating cash flow of $0.95 million in Q1 2026.

Outlook and guidance

• Management expects to capitalize on industry transformation following cannabis rescheduling and ongoing growth drivers in 2026.

• Continued focus on branded product expansion, market penetration, and operational efficiency.

• Asset-light licensing and MSA structures expected to drive long-term growth with limited capital investment.

• Delaware adult-use and Pennsylvania expansion seen as near-term catalysts.